WO2006101920A3 - Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage - Google Patents

Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage Download PDF

Info

Publication number
WO2006101920A3
WO2006101920A3 PCT/US2006/009390 US2006009390W WO2006101920A3 WO 2006101920 A3 WO2006101920 A3 WO 2006101920A3 US 2006009390 W US2006009390 W US 2006009390W WO 2006101920 A3 WO2006101920 A3 WO 2006101920A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
adenosine
manipulation
receptor signaling
Prior art date
Application number
PCT/US2006/009390
Other languages
French (fr)
Other versions
WO2006101920A2 (en
Inventor
Stephen Dewhurst
Servio Ramirez
Shao-Ming Lu
Harris A Gelbard
Sanjay B Maggirwar
Shongshan Fan
Original Assignee
Univ Rochester
Stephen Dewhurst
Servio Ramirez
Shao-Ming Lu
Harris A Gelbard
Sanjay B Maggirwar
Shongshan Fan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Stephen Dewhurst, Servio Ramirez, Shao-Ming Lu, Harris A Gelbard, Sanjay B Maggirwar, Shongshan Fan filed Critical Univ Rochester
Publication of WO2006101920A2 publication Critical patent/WO2006101920A2/en
Publication of WO2006101920A3 publication Critical patent/WO2006101920A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

Provided herein are compositions and methods relating to the treatment and prevention of HTV-1 associated dementia (HAD) utilizing a modulator of adenosine receptor signaling.
PCT/US2006/009390 2005-03-18 2006-03-16 Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage WO2006101920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66305905P 2005-03-18 2005-03-18
US60/663,059 2005-03-18

Publications (2)

Publication Number Publication Date
WO2006101920A2 WO2006101920A2 (en) 2006-09-28
WO2006101920A3 true WO2006101920A3 (en) 2007-02-15

Family

ID=37024367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009390 WO2006101920A2 (en) 2005-03-18 2006-03-16 Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage

Country Status (1)

Country Link
WO (1) WO2006101920A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000113A (en) 2009-06-30 2012-02-29 Forest Lab Holdings Ltd ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A<sub>2A </sub>R AGONISTS.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6063775A (en) * 1997-04-29 2000-05-16 Berman; Charles L. Retardation of metalloproteinase incidental to HIV and/or AIDS
US20030162695A1 (en) * 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6063775A (en) * 1997-04-29 2000-05-16 Berman; Charles L. Retardation of metalloproteinase incidental to HIV and/or AIDS
US20030162695A1 (en) * 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORTHERINGHAM ET AL.: "Adenosine receptor control HIV-1 Tat-inflammatory response through protein phosphatase", VIROLOGY, vol. 327, 2004, pages 186 - 195, XP003007465 *
JONES ET AL.: "Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists", NEUROSCIENCE, vol. 85, no. 1, 1998, pages 229 - 237, XP001005922 *

Also Published As

Publication number Publication date
WO2006101920A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
HUS2100022I1 (en) Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity
USD639692S1 (en) Earring
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
CA121779S (en) Cover plate for a headset
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2006066014A3 (en) Backplane design for display panels and processes for their manufacture
WO2008127364A3 (en) Antiviral compounds and use thereof
EP1790638A4 (en) Carbamoylpyridone derivative having hiv integrase inhibitory activity
EP2518079A3 (en) HCV/HIV inhibitors and their uses
WO2009024107A8 (en) Modular endoscope
WO2007029087A3 (en) Controlled release multiple unit formulations
WO2007003264A3 (en) Polyaspartic acid derivatives in covering agents containing polysiloxane
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
WO2006101920A3 (en) Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage
WO2008122876A3 (en) Modular piece of jewellery
IL189939A0 (en) Inhibitors of the hiv integrase enzyme
USD606205S1 (en) Hydrotherapy apparatus
WO2008097341A3 (en) Antiviral compounds and use thereof
AU2006903796A0 (en) Hellicoptor safety pod. Or &#34; &#34;rotortip &#34; &#34; pod.
AU317901S (en) My ancestral wheel. The genealogy display board. Student edition.
WO2006079649A3 (en) Tool for producing a border on a drinking straw
AU2004901204A0 (en) Plant (Machinery) Fall Arrest System

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06738452

Country of ref document: EP

Kind code of ref document: A2